Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65.8M
-
Number of holders
-
175
-
Total 13F shares, excl. options
-
70.7M
-
Shares change
-
-2M
-
Total reported value, excl. options
-
$1.83B
-
Value change
-
-$41M
-
Put/Call ratio
-
2.31
-
Number of buys
-
87
-
Number of sells
-
-82
-
Price
-
$25.87
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q3 2025
213 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q3 2025.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 175 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.7M shares
.
Largest 10 shareholders include Kynam Capital Management, LP (6.1M shares), WELLINGTON MANAGEMENT GROUP LLP (5.8M shares), BlackRock, Inc. (5.51M shares), FMR LLC (4.96M shares), VANGUARD GROUP INC (3.95M shares), Point72 Asset Management, L.P. (3.89M shares), Bellevue Group AG (3.56M shares), Commodore Capital LP (3.03M shares), STATE STREET CORP (2.84M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (2.38M shares).
This table shows the top 175 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.